quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:00:00·22h
PRRelease
Koninklijke Philips N.V. NY Registry Shares logo

Philips launches new Bridge Plus Occlusion Balloon to help manage rare but life-threatening SVC tears during lead extraction

PHG· Koninklijke Philips N.V. NY Registry Shares
Health Care
Original source

Companies

  • PHG
    Koninklijke Philips N.V. NY Registry Shares
    Health Care

Recent analyst ratings

  • Dec 17UpdateRBC Capital Mkts-
  • Feb 25UpdateExane BNP Paribas-
  • Feb 20UpdateUBS-
  • Oct 29UpdateJefferies-
  • May 13UpdateBernstein-
  • May 7UpdateExane BNP Paribas-

Related

  • PR1d
    Philips receives FDA 510(k) clearance for its Rembra platform, expanding access to faster, more precise CT imaging across frontline care and cancer treatment planning
  • PR7d
    Philips receives FDA 510(k) clearance for Verida, the world's first AI-powered detector-based spectral CT*, advancing diagnostic precision across clinical applications
  • SEC24d
    SEC Form 6-K filed by Koninklijke Philips N.V. NY Registry Shares
  • SEC24d
    SEC Form 6-K filed by Koninklijke Philips N.V. NY Registry Shares
  • PR28d
    FDA clears Philips AI solution that provides real-time guidance during complex minimally invasive heart valve repair
  • PR30d
    Philips launches IntraSight Plus to simplify coronary interventions and advance precision care
  • PR31d
    Philips remains No. 1 in Medtech at European Patent Office and the largest Dutch patent applicant
  • PR32d
    Philips convenes the Annual General Meeting of Shareholders 2026
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022